Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01936324
Recruitment Status : Completed
First Posted : September 6, 2013
Results First Posted : May 10, 2019
Last Update Posted : May 27, 2019
Sponsor:
Information provided by (Responsible Party):
Dermira, Inc.

Brief Summary:

This is a Phase 1/2a study.

The purpose of Phase 1 was to evaluate the safety and tolerability of DRM01B Topical Gel in 6 healthy volunteers.

The purpose of Phase 2a was to assess the safety, tolerability and preliminary efficacy of DRM01B Topical Gel compared to vehicle in subjects with acne vulgaris on the face.


Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Olumacostat Glasaretil Gel, 7.5% Other: Olumacostat Glasaretil Gel, Vehicle Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris
Study Start Date : August 2013
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: Phase 1
Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
Drug: Olumacostat Glasaretil Gel, 7.5%
Gel containing Olumacostat Glasaretil
Other Name: DRM01

Experimental: Phase 2a
Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
Drug: Olumacostat Glasaretil Gel, 7.5%
Gel containing Olumacostat Glasaretil
Other Name: DRM01

Other: Olumacostat Glasaretil Gel, Vehicle
Vehicle (placebo) gel




Primary Outcome Measures :
  1. Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a [ Time Frame: Baseline and Week 12 ]
    Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a

  2. Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a [ Time Frame: Baseline and Week 12 ]
    Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a

  3. Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a [ Time Frame: Baseline and Week 12 ]

    Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a

    Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions

    1. - Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
    2. - Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
    3. - Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
    4. - Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Phase 1 Inclusion Criteria

  1. Signed informed consent
  2. Willing to comply with the requirements of the protocol
  3. Males or non-pregnant, non-lactating females
  4. Age ≥ 18 years
  5. Was in good health and free from any clinically significant disease, as determined by the investigator
  6. If female and of childbearing potential, was willing to use an accepted method of birth control during study participation and for 30 days after the last application of study drug. Females were considered to be of childbearing potential unless they had been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had been diagnosed as infertile, had a same-sex partner or vasectomized male partner, were postmenopausal for at least 1 year, or were abstinent. Acceptable methods of birth control were defined as: abstinence, oral contraceptives, contraceptive patches/implants; Depo-Provera®, double barrier methods (e.g., condom and spermicide) or an intrauterine device (IUD). The birth control method must have been stable/unchanged for 30 days prior to baseline.
  7. If male, was vasectomized or agreed to use an accepted method of birth control with female partner during study participation and for 30 days after the last application of study drug.

Phase 1 Exclusion Criteria

  1. Females who were pregnant, planning to become pregnant during the course of the study, or were breast-feeding
  2. Had a known hypersensitivity to DRM01B or its excipients
  3. Had any skin condition that may have interfered with the safety evaluations during the study
  4. Had a clinical chemistry or hematology laboratory value at screening that was considered clinically significant, in the opinion of the investigator
  5. Participated in an investigational drug study within 30 days prior to screening
  6. Were considered a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator. Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.

Phase 2a Inclusion Criteria

  1. Signed informed consent
  2. Willing to comply with the requirements of the protocol
  3. Male or non-pregnant, non-lactating females
  4. Age ≥ 18 years
  5. If female and of childbearing potential, was willing to use an accepted method of birth control during study participation and for 30 days after the last study drug application. Females were considered to be of childbearing potential unless surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had been diagnosed as infertile, had same sex partner or vasectomized male partner, or were postmenopausal for at least 1 year. Acceptable methods of birth control were defined as: abstinence, oral contraceptives, contraceptive patches/implants; Depo-Provera®, double barrier methods (e.g., condom and spermicide) or an IUD. The birth control method must have been stable/unchanged for 12 weeks prior to baseline and must have remained unchanged during study participation.
  6. If male, was vasectomized or agreed to use an accepted method of birth control with female partner during study participation and for 30 days after the last study drug application.
  7. Subjects were in good health and free from any disease that, in the opinion of the investigator, would have put the subject at risk during participation in the study.
  8. Clinical diagnosis of facial acne vulgaris defined as:

    • At least 20 inflammatory lesions
    • At least 20 noninflammatory lesions
    • IGA of 3 or greater
  9. Willing to refrain from using any treatments, other than the investigational product, including antibiotics, for acne present on the face. Topical acne treatments that did not have significant or measurable systemic absorption (e.g., benzoyl peroxide, salicylic acid) were allowed for treatment of acne of the back, shoulders, and chest only.

Phase 2a Exclusion Criteria

  1. Females who were pregnant, planning to become pregnant during the course of the study, or breast-feeding
  2. Had a known hypersensitivity to DRM01B or its excipients
  3. Had any skin condition that may have interfered with evaluation of safety or acne vulgaris (e.g., rosacea; seborrheic dermatitis; perioral dermatitis; corticosteroid-induced acne or folliculitis)
  4. Had excessive facial hair that would have interfered with diagnosis or assessment of acne vulgaris
  5. Had excessive sun exposure, in the opinion of the investigator, or use of tanning booths
  6. Had active cystic acne or acne conglobata, acne fulminans, and secondary acne
  7. Had 2 or more active nodular lesions
  8. Had a clinical chemistry or hematology laboratory value at screening that was considered clinically significant, in the opinion of the investigator
  9. Participated in an investigational drug study within 30 days prior to screening
  10. Subjects who were a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator
  11. Any other condition that, in the judgment of the investigator, would have put the subject at unacceptable risk during participation in the study
  12. Treatment with over-the-counter (OTC) topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline
  13. Treatment with systemic corticosteroids within 4 weeks prior to baseline (Note: use of intranasal and inhaled corticosteroids was allowed for seasonal allergies and asthma)
  14. Treatment with systemic antibiotics, systemic anti-acne drugs, or systemic anti-inflammatory drugs within 4 weeks prior to baseline
  15. Prescription topical retinoid use on the face within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene).
  16. Treatment with a new hormonal therapy or dose change to an existing hormonal therapy within 12 weeks prior to baseline. The dose and frequency of use of any hormonal therapy started more than 12 weeks prior to baseline must have remained unchanged throughout the study. Hormonal therapies included, but were not limited to, estrogenic and progestational agents, such as birth control pills.
  17. Prior use of androgen receptor blockers (such as spironolactone or flutamide)
  18. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline
  19. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks or during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01936324


Locations
Layout table for location information
Canada, British Columbia
Guildford Dermatology Specialist Inc
Surrey, British Columbia, Canada, V3R 6A7
Canada, Ontario
Ultranova Skincare
Barrie, Ontario, Canada, L4M 6L2
Lynderm Research Inc
Markham, Ontario, Canada, L3P1A8
Institute of Cosmetic & Laser Surgery
Oakville, Ontario, Canada, L6J 7W5
Skin Centre for Dermatology
Peterborough, Ontario, Canada, K9J 1Z2
The Centre for Dermatology
Richmond Hill, Ontario, Canada, L4B 1A5
Research Toronto
Toronto, Ontario, Canada, M5S 3B4
K. Papp Clinical Research Inc.
Waterloo, Ontario, Canada, N2J 1C4
Windsor Clinical Research, Inc.
Windsor, Ontario, Canada, N8W 5W7
Canada, Quebec
Innovaderm Research, Inc
Montreal, Quebec, Canada, H2K 4L5
Siena Medical Research
Montreal, Quebec, Canada, H3Z 2S6
Canada
Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)
Quebec, Canada, G1V 4X7
Sponsors and Collaborators
Dermira, Inc.
Investigators
Layout table for investigator information
Study Director: Janice Drew Dermira, Inc.

Layout table for additonal information
Responsible Party: Dermira, Inc.
ClinicalTrials.gov Identifier: NCT01936324     History of Changes
Other Study ID Numbers: DRM01B-ACN01
First Posted: September 6, 2013    Key Record Dates
Results First Posted: May 10, 2019
Last Update Posted: May 27, 2019
Last Verified: May 2019
Keywords provided by Dermira, Inc.:
acne vulgaris
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases